AstraZeneca could start profiting from its COVID-19 vaccine as soon as July next year, the Financial Times reported on Wednesday, citing a memo showing the British drugmaker can declare when it considers the pandemic to have ended.The London-listed firm previously said it would not profit from the vaccine "during the pandemic", and the report attributes the development to a memorandum of understanding signed this year between AstraZeneca and Brazilian public health organization, Fiocruz.AstraZeneca, which developed the vaccine with Oxford University, signed multiple supply-and-manufacture deals for more than 3 billion doses globally, although details on the terms have been scant.According to FT, the "Pandemic Period" could be further.